The Cancer

Don't Miss

Childhood Most cancers Survivors Face Lengthy-Time period Meningioma Danger

Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...

Professional Discusses FDA Approval of Chemo-Free Possibility for EGFR-Mutated Lung Most cancers

The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...

FDA Clears Protocol Replace for Tasquinimod in Myelofibrosis Trial

Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...

Vital Information

Facts

Latest Articles

Registration Open for the Nationwide Caregivers Self-Care and Instruments Webinar Hosted by the Finish Mind Most cancers Initiative

Registration is now open for the Nationwide Caregivers Self-Care and Instruments on-line instructional occasion on November seventh, 2025 at 11AM Pacific Time,...

Discovering Love and Humanity within the Radiation Ready Room

Many individuals have written about most cancers and their experiences. All have been private, caring, empathetic, loving, other-centered, humbling, tear-filled and joy-filled....

Gastrointestinal Stromal Tumor: Complete Affected person Information

What Are Gastrointestinal Stromal Tumors (GISTs)?Gastrointestinal stromal tumors, or GISTs, are uncommon cancers that kind within the digestive tract, mostly within the...

FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome

The U.S. Meals and Drug Administration has granted orphan drug designation to the investigational remedy MNV-201 for sufferers with myelodysplastic syndrome, a...

Jakafi Trial Reveals Advantages for Sufferers with Myelofibrosis and Anemia

For sufferers with myelofibrosis who had anemia at prognosis and obtained erythropoiesis-stimulating brokers (ESAs) or danazol together with Jakafi (ruxolitinib), enhancements in...

Hot Topics